You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生制药(01177.HK)派安普利单抗相关临床数据摘要获ASCO年会接受以海报形式呈列
阿思达克 05-19 12:06
中国生物制药(01177.HK)公布,由集团与康方生物(09926.HK)共同开发及商业化的派安普利单抗(AK105,PD-1单抗)联合安罗替尼一线治疗晚期肝细胞癌的临床疗效和安全性二期研究数据摘要,已获即将召开的今年美国临床肿瘤学会(ASCO)年会接受以海报形式呈列。

此次将在ASCO发布的研究数据涉及的研究分为Ib/II期研究,为派安普利(200mgQ3W)联合盐酸安罗替尼8mg,每日一次,连续2周停1周(n31)。肿瘤缓解情况评估使用的是1.1版的实体瘤疗效评估标准。

派安普利单抗是处於临床开发後期、具差异化的PD-1创新性单克隆抗体候选药物。安罗替尼是集团自主研发的1类口服、新型小分子多靶点酪氨酸激(酉每)抑制剂,具有抗肿瘤血管生成和抑制肿瘤生长的作用。(ek/a)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account